EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transformed but Not Cured: The Ethics of Describing Gene‐Editing Therapy for Sickle Cell Disease

Jada Wiggleton-Little, Shameka Poetry Thomas, Kristin Walters, Consuela Albright

Hastings Center Report · 2026-05 · 56 (3) · 9-14

DOI: 10.1002/hast.70033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hastings Center Report, online erschienen am 06.05.2026. Verfasst von Jada Wiggleton-Little und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Genetic Therapy, Gene Editing. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In December 2023, the U.S. Food and Drug Administration approved gene‐editing therapies as sickle cell disease treatments. Such approvals for gene‐editing not only mark radical scientific innovations for populations living with sickle cell disease (SCD) across the United States but also generate an expectation of a potential cure—the end or eradication of an illness and its effects. This essay, however, cautions against framing gene‐editing therapy as a “cure” for SCD. Our argument illustrates that, even if gene editing is proven to permanently normalize the hematologic function of the body, there are other painful aspects of SCD that gene editing is unable to transform. Scientific researchers and health care practitioners could benefit from further bioethical consideration of the effects of using curative language with regards to SCD. The curative framing can easily generate misunderstandings in patient‐provider communication and elicit unrealistic expectations. Raising awareness about the importance of how gene‐editing therapies for SCD are described and about the need to discuss their limitations can prevent further harm .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellGenetic TherapyGene EditingHumansUnited States

Stichwörter der Autor:innen

SCDbioethicscuredoctor‐patient communicationgene editinglived experiencepainsickle cell disease

Zitieren

APA

Wiggleton-Little, J., Thomas, S. P., Walters, K., & Albright, C. (2026). Transformed but Not Cured: The Ethics of Describing Gene‐Editing Therapy for Sickle Cell Disease. Hastings Center Report, 56(3), 9-14. https://doi.org/10.1002/hast.70033

Vancouver

Wiggleton-Little J, Thomas SP, Walters K, Albright C. Transformed but Not Cured: The Ethics of Describing Gene‐Editing Therapy for Sickle Cell Disease. Hastings Center Report. 2026;56(3):9-14. doi:10.1002/hast.70033

BibTeX
@article{WiggletonLittle2026,
  author = {Wiggleton-Little, Jada and Thomas, Shameka Poetry and Walters, Kristin and Albright, Consuela},
  title = {Transformed but Not Cured: The Ethics of Describing Gene‐Editing Therapy for Sickle Cell Disease},
  journal = {Hastings Center Report},
  year = {2026},
  volume = {56},
  number = {3},
  pages = {9--14},
  doi = {10.1002/hast.70033}
}
Kostenlos starten →